Patients of the placebo group | ||||
Degrees of hearingloss | RE (N˚ ptes) | Percentage RE | LE (N˚ ptes) | Percentage LE |
Mild to moderate: 25 - 49 dBs | 15 | 75.00% | 6 | 30.00% |
Moderate to severe: 50 - 59 dBs | 5 | 25.00% | 6 | 30.00% |
Severe: 60 to 74 dBs | - | - | 8 | 40.00% |
Profound: >75 dBs | - | - | - |
|
Patients of the deflazacort group | ||||
Mild to moderate: 25 - 49 dBs | 10 | 45.00% | 14 | 63.60% |
Moderate to severe: 50 - 59 dBs | 5 | 22.70% | 3 | 13.60% |
Severe: 60 to 74 dBs | 5 | 22.70% | 3 | 13.60% |
Profound: >75 dBs | 2 | 9.60 | 2 | 9.20% |
Patients of the fludrocortisone group | ||||
Mild to moderate: 25 - 49 dBs | 16 | 61.50% | 18 | 69.20% |
Moderate to severe: 50 - 59 dBs | 3 | 11.60% | 3 | 11.60% |
Severe: 60 to 74 dBs | 7 | 26.90% | 4 | 15.30% |
Profound: >75 dBs | - | - | 1 | 3.90% |
Patients of the nimodipine group | ||||
Mild to moderate: 25 - 49 dBs | 12 | 54.50% | 14 | 63.60% |
Moderate to severe: 50 - 59 dBs | 4 | 18.10% | 2 | 9.30% |
Severe: 60 to 74 dBs | 4 | 18.10% | 6 | 27.10% |
Profound: >75 dBs | 2 | 9.30% | - | - |